» Authors » Steven I Dworetzky

Steven I Dworetzky

Explore the profile of Steven I Dworetzky including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 25
Citations 366
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Siddiqui S, Wenzel S, Bozik M, Archibald D, Dworetzky S, Mather J, et al.
J Allergy Clin Immunol . 2023 Jun; 152(5):1121-1130.e10. PMID: 37277072
Background: There is a need for new and effective oral asthma therapies. Dexpramipexole, an oral eosinophil-lowering drug, has not previously been studied in asthma. Objective: We sought to evaluate the...
2.
Laidlaw T, Prussin C, Panettieri R, Lee S, Ferguson B, Adappa N, et al.
Laryngoscope . 2018 Oct; 129(2):E61-E66. PMID: 30284267
Objective: Chronic rhinosinusitis with nasal polyps (CRSwNP) and eosinophilia is a disease of the upper respiratory tract for which few therapies are available. Because the oral investigational drug dexpramipexole serendipitously...
3.
Panch S, Bozik M, Brown T, Makiya M, Prussin C, Archibald D, et al.
Blood . 2018 May; 132(5):501-509. PMID: 29739754
Hypereosinophilic syndromes (HESs) are a heterogeneous group of disorders characterized by peripheral eosinophilia and eosinophil-related end organ damage. Whereas most patients respond to glucocorticoid (GC) therapy, high doses are often...
4.
Dworetzky S, Hebrank G, Archibald D, Reynolds I, Farwell W, Bozik M
Blood Cells Mol Dis . 2017 Feb; 63:62-65. PMID: 28178599
Dexpramipexole, an orally bioavailable small molecule previously under clinical development in amyotrophic lateral sclerosis, was observed during routine safety hematology monitoring to demonstrate pronounced, dose- and time-dependent eosinophil-lowering effects, with...
5.
6.
Alavian K, Dworetzky S, Bonanni L, Zhang P, Sacchetti S, Li H, et al.
Mol Pharmacol . 2014 Oct; 87(1):1-8. PMID: 25332381
Inefficiency of oxidative phosphorylation can result from futile leak conductance through the inner mitochondrial membrane. Stress or injury may exacerbate this leak conductance, putting cells, and particularly neurons, at risk...
7.
Wu Y, Conway C, Sun L, Machet F, Chen J, Chen P, et al.
Bioorg Med Chem Lett . 2013 Sep; 23(22):6188-91. PMID: 24070783
Acrylamide (S)-6, a potent and efficacious KCNQ2 (Kv7.2) opener, demonstrated significant activity in two models of neuropathic pain and in the formalin test, suggesting that KCNQ2 openers may be useful...
8.
Mcdonald I, Mate R, Zusi F, Huang H, Post-Munson D, Ferrante M, et al.
Bioorg Med Chem Lett . 2013 Feb; 23(6):1684-8. PMID: 23414838
High throughput screening led to the identification of a novel series of quinolone α7 nicotinic acetylcholine receptor (nAChR) agonists. Optimization of an HTS hit (1) led to 4-phenyl-1-(quinuclidin-3-ylmethyl)quinolin-2(1H)-one, which was...
9.
Alavian K, Dworetzky S, Bonanni L, Zhang P, Sacchetti S, Mariggio M, et al.
Brain Res . 2012 Feb; 1446:1-11. PMID: 22364637
Cellular stress or injury can result in mitochondrial dysfunction, which has been linked to many chronic neurological disorders including amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). Stressed and dysfunctional...
10.
Vrudhula V, Dasgupta B, Qian-Cutrone J, Kozlowski E, Boissard C, Dworetzky S, et al.
J Med Chem . 2007 Feb; 50(5):1050-7. PMID: 17274609
The synthesis of a series of 3-beta-hydroxyethyl-4-arylquinolin-2-ones is described. These compounds contain hydrophilic and hydrophobic substituents ortho to the phenolic OH in the C ring of the quinolinone. Electrophysiological evaluation...